Senator Lee,
Thank you for the work you and the Senate Human Services Committee have undertaken to date on patient safety. We share the belief that prioritizing patient safety is paramount to ensuring patients have confidence in the care they receive. This shared belief is a good starting point for collaboration to ensure patients have the most accurate and up-to-date information about their care. To that end, I'd like to correct a data point in response to AARP North Dakota's committee testimony on Tuesday, March 16 on SB 2170.

I think it important that you know that, Retin-A and Restasis, the two products referenced by the witness from AARP, are not manufactured by any of the Janssen pharmaceutical companies of Johnson & Johnson as claimed by the witness. Regardless of who is the manufacturer, medicines that are imported into the United States through channels that circumvent the robust safety, efficacy, and quality standards of the medicine supply chain pose a serious public health risk while also lacking clear evidence the process will make medicines more affordable for patients.

I'd welcome the opportunity to talk about these broader issues with you at your convenience. Thank you for your time.

Regards,

Sharon D'Agostino
Senior Director, State Government Affairs

Johnson & Johnson
Worldwide Government Affairs & Policy
M: +1 612-799-4961
sdagost1@its.jnj.com